Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma
- 1 February 2005
- Vol. 103 (3), 576-581
- https://doi.org/10.1002/cncr.20802
Abstract
BACKGROUND This Phase II study was designed to evaluate the efficacy and safety of irinotecan in patients with advanced nasopharyngeal carcinoma (NPC). METHODS Patients with disseminated, undifferentiated NPC that progressed during or within 3 months of platinum‐based and/or taxane‐based regimen were eligible. Irinotecan at a dose of 100 mg/m2 was administered on Days 1, 8, and 15 every 28 days, up to a maximum of 6 cycles, until disease progression or the appearance of intolerable toxicity. RESULTS Twenty‐eight patients were evaluable for toxicity and response. Patient characteristics were as follows: The median age was 46.5 years (range, 40.3–71.6 years), the median number of prior lines of chemotherapy was 2 (range, 1–9), the majority of patients (89%) had good Eastern Cooperative Oncology Group performance status (0–1), and the majority of patients (82.1%) had ≥ 2 sites of distant metastases. A total of 79 cycles of irinotecan with a median of 3 cycles per patient were administered. Toxicity > Grade 3 included neutropenia in 5 patients (17%), anemia in 5 patients (17%), and diarrhea in 4 patients (14%). The best response outcomes were 4 patients (14%) who achieved partial responses and 1 patient (4%) who achieved stable disease. Global quality‐of‐life scores were stable during treatment. Using the Kaplan–Meier method, the median progression‐free survival was 3.9 months, and the median overall survival was 11.4 months. The partial responders had a durable response (range, 5.7–12.2 months). CONCLUSIONS Results from this trial suggest that irinotecan is an active salvage agent with modest toxicity in patients with advanced NPC who are refractory to platinum/taxane‐based chemotherapy. Studies combining irinotecan with other active agents in the first‐line setting are warranted. Cancer 2005. © 2004 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated typeAnnals of Oncology, 2002
- Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtypeAnnals of Oncology, 1999
- Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinomaAnnals Of Oncology, 1999
- Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancerAnnals of Oncology, 1998
- Pancreatic Cancer: Current status and future directions in the perioperative treatment of pancreatic cancerAnnals of Oncology, 1994
- A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinomaCancer, 1994
- Epstein-Barr Virus Infection, Salted Fish and Nasopharyngeal Carcinoma: A case-control study in SouthernActa Oncologica, 1994
- Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 casesBritish Journal of Cancer, 1993
- Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.Journal of Clinical Oncology, 1991
- Histopathology of nasopharyngeal carcinoma.Correlations with epidemiology, survival rates and other biological characteristicsCancer, 1979